You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

CLINICAL TRIALS PROFILE FOR CLOBEX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Clobex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00400725 ↗ Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis Completed Galderma Phase 3 2006-09-01 The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.
NCT00400725 ↗ Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis Completed Galderma R&D Phase 3 2006-09-01 The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.
NCT00436540 ↗ A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam Completed Galderma Laboratories, L.P. Phase 4 2006-03-01 The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.
NCT00437216 ↗ Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis Completed Galderma Laboratories, L.P. 2006-02-01 Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clobex

Condition Name

Condition Name for Clobex
Intervention Trials
Plaque Psoriasis 4
Psoriasis 4
Scalp Psoriasis 2
Plaque-Type Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clobex
Intervention Trials
Psoriasis 12
Erythema Multiforme 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clobex

Trials by Country

Trials by Country for Clobex
Location Trials
United States 29
Canada 2
France 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clobex
Location Trials
California 5
Texas 5
New York 3
Minnesota 3
Michigan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clobex

Clinical Trial Phase

Clinical Trial Phase for Clobex
Clinical Trial Phase Trials
Phase 4 8
Phase 3 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clobex
Clinical Trial Phase Trials
Completed 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clobex

Sponsor Name

Sponsor Name for Clobex
Sponsor Trials
Galderma Laboratories, L.P. 7
Galderma 2
Galderma R&D 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clobex
Sponsor Trials
Industry 16
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Clobetasol Propionate (CLOBEX)

Introduction to Clobetasol Propionate (CLOBEX)

Clobetasol propionate, commonly known by the brand name CLOBEX, is a potent topical corticosteroid used to treat various inflammatory skin conditions and other medical ailments. Here, we will delve into recent clinical trials, market analysis, and future projections for this drug.

Recent Clinical Trials

Oral Lichen Planus (OLP)

A recent systematic review and meta-analysis of 17 randomized clinical trials highlighted the efficacy and safety of clobetasol propionate (CLO) in treating Oral Lichen Planus (OLP). The results indicated significant improvements in lesion size and symptomatic relief for OLP patients treated with CLO. The study found no statistical incidence of adverse events or relapse compared to other therapies, supporting the long-term application of CLO as an effective regimen for OLP patients[1].

Ocular Surgery

Salvat Laboratories presented the results of Phase III clinical trials for clobetasol 0.05% ophthalmic nanoemulsion (SVT-15473) at the 2023 ARVO Annual Meeting. These trials, conducted between 2020 and 2021, involved over 400 patients in more than 40 specialized centers in the United States. The data showed that clobetasol was effective in reducing inflammation and pain post-ocular surgery, with low impact on intraocular pressure and no rebound effect after treatment. This innovative nanoemulsion formulation offers superior advantages over other corticosteroids, including better coverage and absorption without causing blurred vision or discomfort[4].

Market Analysis

Current Market Position

Clobetasol propionate is widely used in dermatology and ophthalmology for its potent anti-inflammatory properties. The drug's effectiveness in treating various conditions, such as psoriasis, eczema, and post-ocular surgery inflammation, has established it as a staple in medical treatment protocols.

Market Growth Drivers

The market for clobetasol propionate is driven by several factors:

  • Increasing Incidence of Skin Conditions: The rising incidence of chronic inflammatory skin diseases, such as atopic dermatitis and psoriasis, contributes to the demand for effective treatments like clobetasol propionate.
  • Advancements in Drug Delivery: Innovations like the nanoemulsion formulation by Salvat Laboratories enhance the drug's efficacy and patient comfort, potentially increasing its market share[4].

Competitive Landscape

The market for topical corticosteroids is competitive, with several other treatments available. However, clobetasol propionate's potency and the advancements in its formulation, such as the nanoemulsion technology, give it a competitive edge. Other treatments, like immunotherapies and targeted therapies, are also evolving, but clobetasol propionate remains a preferred option for many dermatological and ophthalmological conditions.

Market Projections

Global Demand

The global demand for clobetasol propionate is expected to grow due to its versatility and effectiveness. The increasing incidence of skin conditions and the need for potent anti-inflammatory treatments will drive this growth.

Regional Market Trends

  • United States and Europe: These regions are expected to continue as major markets for clobetasol propionate, driven by the high prevalence of skin conditions and the availability of advanced healthcare services.
  • Asia-Pacific: Countries like China are expected to see significant growth in the demand for clobetasol propionate, driven by an increasing incidence of skin diseases and improving healthcare infrastructure[2].

Financial Projections

While specific financial projections for clobetasol propionate are not available, the overall market for dermatological and ophthalmological treatments is expected to grow substantially. For instance, the global pharmaceutical CRO market, which includes services related to the development of such drugs, is projected to reach USD 62.99 billion by 2030, growing at a CAGR of 7.39% from 2025 to 2030[5].

Key Takeaways

  • Efficacy and Safety: Recent clinical trials have reinforced the efficacy and safety of clobetasol propionate in treating various conditions, including OLP and post-ocular surgery inflammation.
  • Innovative Formulations: Advancements in drug delivery technologies, such as nanoemulsion formulations, are enhancing the drug's performance and patient comfort.
  • Market Growth: The market for clobetasol propionate is expected to grow driven by increasing incidence of skin conditions and advancements in healthcare.
  • Competitive Edge: Clobetasol propionate's potency and innovative formulations give it a competitive edge in the market for topical corticosteroids.

FAQs

What is clobetasol propionate used for?

Clobetasol propionate is a potent topical corticosteroid used to treat various inflammatory skin conditions, such as psoriasis, eczema, and oral lichen planus, as well as inflammation and pain post-ocular surgery.

What are the recent clinical trial findings for clobetasol propionate?

Recent clinical trials have shown that clobetasol propionate is effective in treating oral lichen planus and reducing inflammation and pain post-ocular surgery, with low adverse event rates and no rebound effect after treatment.

How is the market for clobetasol propionate expected to grow?

The market for clobetasol propionate is expected to grow due to increasing incidence of skin conditions, advancements in drug delivery technologies, and the drug's established efficacy and safety profile.

What are the competitive advantages of clobetasol propionate?

Clobetasol propionate's potency, innovative formulations like nanoemulsion technology, and its effectiveness in treating a range of conditions give it a competitive edge in the market.

Are there any new formulations or delivery methods being developed for clobetasol propionate?

Yes, Salvat Laboratories has developed a nanoemulsion formulation of clobetasol propionate, which offers superior advantages over traditional formulations, including better coverage, absorption, and patient comfort.

Sources

  1. Zheng T, Liu C, Wang Y, Zhou R, Wu D, et al. "Efficacy and safety of topical clobetasol propionate in patients with oral lichen planus: A systematic review and meta-analysis." Frontiers in Medicine, 2024.
  2. GlobalData. "NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025."
  3. Celldex Therapeutics. "Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis."
  4. Salvat Laboratories. "Salvat Laboratories presented Phase III clinical trials results of clobetasol nanoemulsion for treating inflammation and pain after ocular surgery at the 2023 ARVO Annual Meeting."
  5. ResearchAndMarkets.com. "Pharmaceutical CRO Market Report 2025-2030, Featuring Parexel, ICON, Laboratory Corporation of America, Thermo Fisher Scientific, Medpace, IQVIA, WuXi AppTec, and Veeda Clinical Research."

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.